VeriChip to launch DTC campaign

Share this article:
VeriChip to launch DTC campaign
VeriChip to launch DTC campaign

The VeriChip Corporation, manufacturers of radio-frequency identification devices (RFID) for patients, launched its first DTC campaign in South Florida.

In conjunction with the campaign, which features print and TV ads, VeriChip renamed its patient identification system Health Link, and launched a new website. Health Link was designed to provide vital medical and emergency contact information to doctors and nurses. 

“Given our successful infrastructure build-out in South Florida, we are now ready to escalate our marketing efforts to increase consumer awareness and adoption through the first DTC launch of our product,” said Scott Silverman, chairman and CEO, in a statement.

VeriChip hired Samuel Ambros to lead the marketing effort as vice president of business development. The company announced a partnership with HearUSA and its HEARx centers to provide customers with easy access to the Health Link system. HEARx has eight locations throughout the Palm Beach market.

The Health Link RFID microchip is injected subcutaneously in the rear upper portion of the right arm. The microchip stores a 16-digit personal identification number. Emergency medical personnel can use the Health Link scanner to retrieve the number, and access to the patient's personal health record.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...